Carisma Therapeutics Inc.

Please note: The information displayed on this page might be outdated.
Carisma Therapeutics Inc.: - CARISMA Therapeutics Inc. is a clinical stage biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. CARISMA Therapeutics is headquartered in Philadelphia, PA.
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
3675 Market Street
Philadelphia, PA 19104
United States

Company Participants at Spring Private Company Showcase

Tom Wilton
Carisma Therapeutics Inc., Chief Business Officer
Tom joined Carisma Therapeutics in September 2019. He brings over 20 years of pharmaceutical and biotechnology industry experience, including corporate strategy, business development, R&D operations and marketing. Tom most recently served as the Chief Business Officer for LogicBio Therapeutics, Inc., a genome editing company, where he was responsible for leading strategy, business development and intellectual property, and supported a successful initial public offering. Prior to LogicBio, Tom was the Chief Business Officer for The University of Pennsylvania’s Gene Therapy Program, where he completed multiple partnerships that enabled the group to grow to over 250 employees. Tom began his career at GlaxoSmithKline, where he was instrumental in establishing the Rare Disease Business Unit and served in various leadership positions in the US and Europe. Tom holds a BS from the University of London, an MA from the University of Leeds, and an MS from Brunel University.